C
Chloe Orkin
Researcher at Queen Mary University of London
Publications - 229
Citations - 14129
Chloe Orkin is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Viral load & Medicine. The author has an hindex of 48, co-authored 202 publications receiving 11614 citations. Previous affiliations of Chloe Orkin include Barts Health NHS Trust & St Bartholomew's Hospital.
Papers
More filters
Journal ArticleDOI
Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study
Hans-Jürgen Stellbrink,Chloe Orkin,Jose R. Arribas,Juliet E. Compston,Jan Gerstoft,Eric Van Wijngaerden,Adriano Lazzarin,Giuliano Rizzardini,Herman G. Sprenger,John D. C. Lambert,Gunta Sture,David Leather,Sara Hughes,Patrizia Zucchi,Helen Pearce +14 more
TL;DR: This study demonstrated the impact of first-line treatment regimens on bone by demonstrating greater increases in bone turnover and decreases in BMD were observed in subjects treated with tenofovir-emtricitabine than were observed with abacavir-lamivudine.
Journal ArticleDOI
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012
Ian Williams,Duncan Churchill,Jane Anderson,Marta Boffito,Mark Bower,Gus Cairns,Kate Cwynarski,Simon Edwards,Sarah Fidler,Martin Fisher,Andrew Freedman,Anna Maria Geretti,Yvonne Gilleece,Rob Horne,Margaret Johnson,Saye Khoo,Clifford Leen,Clifford Leen,Neal Marshall,Mark T. Nelson,Chloe Orkin,Nicholas I. Paton,Andrew N. Phillips,Frank A. Post,Frank A. Post,Anton Pozniak,Caroline A. Sabin,Roy Trevelion,Andrew Ustianowski,John Walsh,Laura Waters,Edmund Wilkins,Alan Winston,Alan Winston,M Youle +34 more
TL;DR: These guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection and at community advocates responsible for promoting the best interests and care of HIV-positive adults.
Journal ArticleDOI
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Paul E. Sax,Kristine M. Erlandson,Jordan E. Lake,Grace A. McComsey,Chloe Orkin,Stefan Esser,Todd T. Brown,Jürgen K. Rockstroh,Xuelian Wei,Christoph C Carter,Lijie Zhong,Diana M. Brainard,Kathleen Melbourne,Moupali Das,Hans Jürgen Stellbrink,Frank A. Post,Laura Waters,John R. Koethe +17 more
TL;DR: Weight gain is ubiquitous in clinical trials of ART initiation and is multifactorial in nature, with demographic factors, HIV-related factors, and the composition of ART regimens as contributors.
Journal ArticleDOI
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study
Margaret T May,Mark Gompels,Valerie Delpech,Kholoud Porter,Frank A. Post,Margaret Johnson,David Dunn,Adrian Palfreeman,Richard Gilson,Brian Gazzard,Teresa Hill,John Walsh,Martin Fisher,Chloe Orkin,Jonathan Ainsworth,Loveleen Bansi,Andrew Phillips,Clifford Leen,Mark Nelson,Mark Nelson,Jane Anderson,Caroline A. Sabin +21 more
TL;DR: Life expectancy in people treated for HIV infection has increased by over 15 years during 1996-2008, but is still about 13 years less than that of the UK population.
Journal ArticleDOI
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial
Jürgen K. Rockstroh,Mark T. Nelson,Christine Katlama,J. Lalezari,Josep Mallolas,Mark Bloch,Gail V. Matthews,Michael S. Saag,Philippe J. Zamor,Chloe Orkin,Jacqueline Gress,Stephanie O. Klopfer,Melissa Shaughnessy,Janice Wahl,Bach-Yen Nguyen,Eliav Barr,Heather L. Platt,Michael N. Robertson,Mark S. Sulkowski +18 more
TL;DR: This HCV treatment regimen seems to be effective and well tolerated for patients co-infected with HIV with or without cirrhosis, and these data are consistent with previous trials of this regimen in the monoinfected population.